On 23 October 2025, the Company published the reorganization plan in its ongoing corporate reorganization (the “Reorganization Plan”), which is also attached in full to this press release. On 24 October 2025, the Company requested that the District Court of Uppsala proceed with a hearing on the Reorganization Plan, a so-called plan negotiation. The District Court of Uppsala has today decided that the plan meeting, during which the relevant parties will have the opportunity to vote on the Reorganization Plan, will take place on 27 November 2025 at 10:00 a.m.

All relevant parties in the corporate reorganization (including creditors and shareholders) are entitled to attend the plan meeting and vote on the Reorganization Plan. Parties who wish to be represented by a proxy, or to grant the administrator a power of attorney to vote on the Reorganization Plan on their behalf, must issue a written and dated power of attorney to such proxy or the administrator, as applicable. Power of attorney forms are available on the Company’s website, www.peptonicmedical.se.

Parties who wish to attend the plan meeting are encouraged to notify the Company in advance via e-mail to info@peptonicmedical.se to ensure sufficient space in the courtroom.

Instructions for Shareholders Wishing to Attend the Plan Meeting

Shareholders of the Company who wish to attend the plan meeting in person or through a proxy must be registered as shareholders in the share register prepared by Euroclear Sweden AB as of 19 November 2025. If a shareholder is represented by a proxy, the written and dated power of attorney signed by the shareholder must also be issued for the proxy and brought in original to the plan meeting.

To be entitled to attend the plan meeting, a shareholder whose shares are nominee-registered must have the shares registered in their own name so that they are included in the share register as of the record date, 19 November 2025. Such registration can be temporary (so-called voting rights registration) and must be requested by the nominee according to the nominee’s procedures within the timeframe determined by the nominee before the record date. Voting rights registrations completed by the nominee no later than 21 November 2025 will be reflected in the preparation of the share register.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                           

Email: anna.linton@peptonicmedical.se                                                                                     

Phone: +46 70-244 92 07

About Peptonic Medical AB                                        

PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.